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Abstract
Background Females carry a better prognosis than men for
many cancer types. We hypothesized that chromosomal
changes, in particular numerical alterations of the sex
chromosomes or the presence of near-triploidy may
contribute to these gender differences.
Methods To characterize the influence of gender a literature
search was performed for survival data of 27 tumor types.
All entities were categorized by the strength of evidence for
differences in survival between females and males. To test
our hypothesis the Mitelman database of chromosomal
alterations was evaluated for the major tumor types
occurring in both women and men. Numerical gonosome
alterations were documented and mean chromosome
numbers were converted into histograms to provide insight
into the ploidy level of 37 cancer types.
Results In general, a survival advantage of women could be
shown for most, but not all cancer types. In addition,
36.859 karyograms were analyzed. Numerical gonosome
alterations were more frequent in males than females
indicating a potential link with gender differences in
survival. Neartriploidy was a common phenomenon in
many cancer types suggesting that it represents a metastable
condition of the cancer genome. It was not related to gender
differences in survival. However, the extent of triploidy and
aneuploidy was associated with poor prognosis in carcino-
mas. There was no single case in the Mitelman database
with normal chromosome number (n=46) that did not carry
at least one structural or numerical aberration.
Conclusions Our study highlights the importance of chro-
mosomal changes in tumor formation and progression. In
addition, it suggests potential associations with gender
specific differences in survival.
Keywords Gender.Aneuploidy.Chromosomal chaos.
Prognosis
1 Introduction
Observations showed that chromosomal alterations and
aneuploidy are associated with the survival of tumor
patients. Furthermore, it is known that there is an
influence of sex on tumor survival. In this work, on the
one hand, we wanted to systematically investigate
whether and if so in which tumor types gender has an
influence on the prognosis. As a predictive value we
used the 5-year survival rate to compare the difference in
survival between men and women. On the other hand the
influence of ploidy on tumor survival should be
investigated.
The term ploidy is related to the chromosome comple-
ment, but also to the DNA content of cells. Aneuploidy is
the state of a cell in which there are numerical aberrations
of chromosomes compared to normal. Aneuploidy may also
occur when structural chromosomal aberrations are associ-
ated with the gain or loss of genetic material. These genetic
imbalances are often detected by a change in the DNA
content of cells [29]. Overall, aneuploidy is a common and
essential characteristic of malignant tumors [20]. Some
authors relate the state of aneuploidy exclusively to
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structural aberrations that are associated with the loss or
gain of chromosomal material [16].
In this paper we used the term aneuploidy primarily in
the context of numerical chromosomal aberrations. A
correlation between aneuploidy and in particular the extent
of chromosomal changes with the survival of cancer
patients has already been shown long time ago [22].
However, in most studies only one tumor was examined
for aneuploidy. There are only few studies which analyzed
several tumor entities [5], [72].
Malignant tumors frequently exhibit DNA distributions
in the near triploid range as we recently pointed out for lung
cancer [60]. Triploidy in cancer can be regarded as
evidence for aneuploidy. It is yet unclear whether this state
of triploidy is related to specific biological or clinicpatho-
logical tumor characteristics.
Specifically, we asked ourselves in this work the
following questions: 1) Which tumor entities show gender
differences in survival? 2) Which tumor types harbour
aneuploid chromosome numbers and have a near triploid
chromosome set? 3) Is there a correlation between triploidy/
aneuploidy and survival? 4) Is there a correlation between
the ploidy level/triploidy or sex chromosome aberrations
and gender-specific difference in cancer survival? More
than 30 tumor entities were analyzed regarding their
survival data and ploidy state.
2 Materials and methods
2.1 Gender-specific prognosis
In this work we examined whether gender could have an
influence on the prognosis. As a predictive value, we
used the 5-year survival rate to compare the difference in
survival between men and women. We examined the
overall survival of 34 tumor entities, including seven
gender-specific tumor types. Data on gender-specific
prognosis were retrieved from PubMed. We took into
account preferentially studies in which the entire tumor
entity was represented, i.e. no studies in which only
certain stages or tumor subgroups (age, etc.) were
considered.
In this respect, there are only few sources that reported
comprehensively on multiple tumor entities. Our main
sources of the survival rate were the Robert Koch Institute
(RKI) and the Eurocare-3 study, this data mainly covered
European and German populations.
In addition, many studies on individual tumor entities
were retrieved in PubMed using the following search
parameters: tumor entity, such as “lung cancer”, “epide-
miology”, “sex specific survival” or “gender-specific
prognosis”. The studies were then summarized in a table
in which the evidence for gender-specific difference in
prognosis is reflected by the number of studies reporting
such differences (Table 1).
2.2 Tumor ploidy
To search for the ploidy in various tumors, we used the
Mitelman database [44]. It represents only modal cancer
cell lines and not all existing sidelines that are present in
these tumors. With the option “Full Searcher” specific
tumor types can be selected. The result is a table that lists
the complete karyotypes of the different tumor cases. These
karyotypes were transferred to Excel. For each karyotype,
we recorded the total chromosome numbers. In some
tumors, only a range of chromosome numbers were
available (e.g. 64–70). For these cases a mean value was
calculated, i.e. minimum plus maximum chromosome
number divided by two, to get a single value for each case
(i.e. 67 in the above mentioned example). The range of the
chromosome numbers of these cases are available as
supplementary data. Importantly, only three cases had
numbers that varied between 46 (minimum) and 92
(maximum) chromosomes (1 colon carcinoma, 1 multiple
myeloma, 1 thyroid carcinoma). These cases were elimi-
nated from the ensuing analysis.
The numbers were then presented in the form of a
histogram (Fig. 1). To simplify the representation, the
tumors were grouped according to a range including cases
with three adjacent chromosome numbers. That means for
example that within the group of diploid tumors not only
those cases with 46 chromosomes but also those with 45
and 47 were included. In general, the histograms represent
the distribution of chromosome numbers within a tumor
entity.
In order to define distinct ploidy states, the proportions
of cases with hyperdiploid, predominant triploid, predom-
inant hypertriploid and aneuploid sets of chromosomes
were calculated. “Hyperdiploid” tumors were classified as
those with chromosome numbers larger than 47 (n>47).
Accordingly, cases with “predominant triploid” karyotpyes
were defined as tumors with chromosome numbers from 57
to 83 (57<n<83). “Predominantly hypertriploid” tumors
were those with n>57. “Aneuploid” tumors were classified
as those with chromosome numbers not in the diploid or
tetraploid range (n≠45–47 and 90–92).
Furthermore, we calculated the proportion of cases
with mutated sex chromosomes in different tumor
entities, i.e. those who did not have the normal XX or
XY karyotype. The comparison between the proportion
of mutant sex chromosomes in tumor entities of women
and men was then represented as a curve diagram
(Fig. 3).
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The data from the ploidy analysis and the calculated
proportion of mutated sex karyotypes were then correlated
with the 5-year survival rates by calculating regression/
correlation coefficients using regression analysis provided
by Excel (Microsoft Office Excel 2007).
3 Results
3.1 Gender-specific survival
Table 1 shows the results of the literature research for
gender-specific survival. We examined 27 tumors that occur
in both sexes, and seven gender-specific malignancies.
According to the number of studies, we characterized the
gender-specific prognosis of the individual tumors. Fur-
thermore, we recorded the 5-year survival rates.
It is apparent that for more than 50% of the tumor
entities, the studies showed a significantly better survival
for women. For instance in malignant melanoma, gastric
cancer and esophageal cancer, all studies reported a survival
advantage of women. Also in lung cancer, all studies except
one indicated a better prognosis of women.
But there were also entities in which the majority of
studies have noted no difference in survival, e.g. in urinary
bladder carcinoma and osteosarcoma.
In a third group of tumors the available data was not
conclusive, the number of trials with similar survival times
in men and women were equal to those reporting a survival
advantage of women.
Overall, just 4 out of 68 analyzed studies reported a
survival advantage of men. Specifically, this was observed
for gall bladder cancer, acute lymphocytic leukemia,
urinary bladder and oral cavity cancer (Table 1).
3.2 Tumor ploidy
In this part of the study the total modal chromosome
numbers of tumors were analyzed and their frequency
distributions represented by a histogram chart (Fig. 1). The
data was retrieved from the Mitelman database of chromo-
somal alterations in cancer. In total, 36.859 karyograms
were analyzed. Based on the histograms it became evident
which chromosome numbers and thus which ploidy level
were most frequently present in the different tumor entities.
Representations of colon cancer, chronic myeloid leukemia,
osteosarcoma and testicular tumors are shown in Fig. 1.
The histograms of all other evaluated tumor entities are
available as supplementary data (supplementary figure 1).
All tumor entities, except testicular tumors, showed a
clear peak of chromosome numbers in the peridiploid
range. In several entities, this was actually the only peak in
the distribution. In AML, CLL, salivary gland tumors and
thyroid carcinomas the tumors were peridiploid in the
overwhelming number of cases. Also CML, ALL, B-cell
lymphomas, the fibroblastic/myofibroblastic tumors, liposar-
coma, Wilms tumor, as well as multiple myeloma showed a
singular diploid peak, but with a somewhat more diffuse
distribution and the presence of hyperdiploid and hypodiploid
cases. The penis and prostate tumors showed also these
peridiploid peaks, but moreover an accumulation of chromo-
some numbers in the tetraploid range was observed.
Several tumors showed chromosome numbers in the
triploidrange,asexemplifiedintheFig.1 for colon carcinoma
and osteosarcoma. Other tumor types of this group were
esophageal carcinoma, gastric carcinoma, gallbladder carci-
noma and lung carcinoma. Also pancreatic carcinoma,
leiomyosarcoma, as well as ovarian cancer showed a similar
distribution which was also detectable in Hodgkin lympho-
ma, malignant fibrous histiocytoma and cervical cancer.
In addition, there is a group of tumors which had
chromosome numbers in the triploid range but without a clear
peak in the frequency distribution. This group includes renal
tumors, malignant melanoma, bladder carcinoma, hepatocel-
lular carcinoma, GIST, astrocytoma grade III-IV, endometrial
tumors, breast cancer and the fibrohistiocytic tumors.
Very unusual is the distribution of chromosome numbers
of testicular tumors which are actually never peridiploid but
instead showed a peak between the diploid and triploid
range (Fig. 1).
We did not analyze the karyograms of 37 tumor types in
the Mitelman database for specific karyotypic changes, but
it was noted that even within the group of diploid tumors
(No. of chromosome=46) there was not a single karyotype
without at least one structural or nummerical aberration.
3.3 Correlation between ploidy and survival
Using a regression analysis, the extent of chromosomal
changes in various tumor entities were compared with the
published survival rates. Specifically, the number of cases
with hyperdiploid, predominant triploid, predominant
hypertriploid and aneuploid chromosome sets were calcu-
lated and correlated with the 5-year survival rates. The
calculated regression/correlation coefficients showed a
significant association between a survival decrease and an
increase of aberrant chromosome numbers in carcinomas
(Fig. 2). In the analysis of all tumor entities, no statistically
significant correlation could be demonstrated.
3.4 Analysis of changes in the sex chromosomes
In Fig. 3, the percentages of mutated sex chromosomes
were represented for those tumor entities that occur in both
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202 S. Schulze, I. Petersenwomen and men. It became evident that the percentage of
numerical sex chromosome aberrations is generally higher
in men compared to women suggesting a potential
association with the gender specific difference in survival.
However, when correlating the percentage differences of
the mutated sex karyotypes with differences in 5-year
survival rates between women and men, no statistically
significant relationship could be established.
4 Discussion
4.1 Differences in gender-specific survival
One aim of this study was to create an overview of the
gender-specific survival in malignant tumors. One earlier
study already presented data for malignant melanoma, soft
tissue sarcoma and cancers of the breast, lung, colorectal,
esophagus, gastric, pancreatic and soft tissue [47]. Except
for pancreas and breast cancer a better survival of women
could be demonstrated. Apart from many individual reports
which examined gender as a possible prognosis parameter
among many others, there are only few comprehensive
studies which deal with this issue in multiple tumor entities.
Noteworthy in this context is the Eurocare-3-study and for
Germany the data of the Robert Koch Institute (RKI).
The Eurocare-3 study examined among other things the
gender-specific survival of 42 different malignancies in
adults and from 24 malignant tumors in children. Overall,
the study included 1.8 million adults and 24,000 children
from 20 European countries who were diagnosed with
cancer during the period from 1990 to 1994. The patients
were observed 5 years after diagnosis until 1999. Various
factors were compared with each other, for example the
survival between countries, the survival among the different
tumors and the survival of women and men. It was
recognized that for most tumors, women had a significantly
better survival [18]. The results of the Robert Koch Institute
represent retrospectively collected data being based on the
information from the tumor registries of individual states of
Germany. Again, an overall survival advantage of women
for most tumor entities could be demonstrated [66]. To our
knowledge, this is the first study which primarily focused
on this issue and analyzed a large number of tumor types
with compilation of data from various reports to provide an
estimate of the evidence for gender specific difference in
cancer survival.
In the literature the following possible causes for the
differences in gender-specific survival are mentioned:
differences in tumor biology, defense mechanisms, percep-
tion of symptoms and stage at the time of diagnosis.
Generally it is stressed that women live healthier, attend
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Fig. 1 Examples for ploidy analysis of tumor entities. Histograms showing the frequency of chromosome numbers in tumor entities for men and
women
Gender and ploidy in cancer survival 203more often screening programs and look for medical advice
earlier than men. Thereby tumors may get detected and
treated at an earlier stage of the disease.
However, many studies taking into account tumor stage
also demonstrated that gender remains a significant and
independent prognostic factor. This could be shown, for
example, in malignant melanoma [64], colorectal [82] and
lung cancer [70]. Thus, it must be postulated that tumor-
biological parameters being associated with the sex of the
patient are responsible for the survival advantage of
women. In addition, the better overall life expectancy of
women need to be considered in this context.
4.2 Ploidy and survival
Another objective of this study was to investigate the ploidy
level of tumors. This was done by analyzing data from the
Mitelman database allowing the assessment of the number of
chromosomes in various tumor entities [44]. A similar
approach was performed recently by Storchova and Kuffer
[72]. These authors, however, placed their emphasis on the
analysis of tetraploidy. In our study, particular attention was
given to the analysis of triploidy, i.e. tumors exhibiting
chromosome numbers in the triploid range, and the question
whether this state has any tumor-biological relevance with
respect to cancer survival and gender-specific prognosis.
Our analysis indicated that many tumor entities have
chromosome numbers with a bimodal distribution with a
peak in the triploid range in addition to a diploid one. This
was observed particularly in tumors with a high mortality
like lung, pancreas, gastric and colon cancer. For lung
cancer, we recently showed that a near triploid DNA
content is frequently detectable in non-small cell carcino-
mas [60]. In fact, Ozaki et al. already reported in 1981 that
near-triploidy represent the most frequent DNA distribution
in lung cancer [54]. Thus, triploidy is not a cell culture
artifact. The observation of tripolar mitoses was indicative
for a DNA peak in the triploid range [60]. Based on the
correlation analysis with survival we could show that the
detection and in particular the extent of triploidy is
associated with poor survival in carcinomas. Triploidy in
this context is obviously correlated with aneuploidy.
In an earlier study by DNA cytometry the bimodal
distribution of chromosome numbers was shown for many
tumors [5]. The authors already pointed to the influence of
the modal DNA value and the ploidy level on prognosis.
For the vast majority of tumors, with the exception of
squamous cell carcinoma of the cervix uteri, a survival
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Fig. 2 Correlation between the extent of (aneu)ploidy states and mean
5-year survival rate in different carcinomas. Each point correspond to
one carcinoma entity as indicated. The survival rates were correlated
with the percentage of cases within each entity showing hyperdiploid
(No.chr.>47), predominant hypertriploid (No.chr .> 57), predominant
triploid (No.chr. 57–83) and aneuploid (No.chr. ≠ 45–47, ≠ 90–92)
chromosome numbers. The correlation coefficients (r) indicate significant
correlations between these (aneu)ploidy states and the 5-year survival rates
204 S. Schulze, I. Petersenbenefit was observed for the near diploid tumors compared
to those in the triploid-tetraploid range [5]. Our study
confirmed that the extent of abnormal chromosome
numbers in carcinomas is associated with worse prognosis
(Fig. 2). This finding again highlights the importance of
aneuploidy and chromosomal chaos for cancer survival. In
addition it suggests that quantifying the amount of non-
diploid cells in carcinomas might be used as a prognostic
marker.
The data for non-carcinoma tumor types is heterogeneous.
Atleastthereisnotsuchaclearassociationbetweentheextent
of triploidy or aneuploidy with survival. In this context, the
analysis of Kaneko and Knudson in neuroblastoma is
interesting. It is one of the few reports that dealt with the
relevance of ploidy level on tumor behavior. The authors
demonstrated that neuroblastoma in lower tumor stages and
with improved survival more frequently had a near triploid
chromosome set while the near diploid tumors were charac-
terized by advanced stages and poor survival [34].
Tripolar mitosis and triploidy are also detectable in
normal cells and are associated with each other as was
already shown more than 40 years ago. Tripolar mitoses
represent a subtype of multipolar mitoses and occur usually
in octaploid or tetraploid cells. During cell division these
cells generate triploid and haploid caughter cells (8n: 3n+
3n+2n, 4n: 3n+1n). However it is a rare phenomenon that
occurred in only 3,6% of the analyzed mitoses [57], [58]. In
malignancies, in contrast, cells with a near triploid
chromosome content frequently represent the predominant
tumor cell clone. And this may be reflected microscopically
by the presence of tripolar mitoses. Thus, triploidy probably
represents a metastable condition of the chromosome
complement.
Our study revealed profound differences in the incidence
of triploidy. In some entities it is detectable very often
while being almost absent in others. This may have
practical importance in the differential diagnosis of malig-
nant undifferentiated tumors of unknown primary site. The
detection of a triploid tumor cell clone by DNA measure-
ment or the observation of tripolar mitoses may provide
important information in this regard.
Testicular tumors revealed a peculiar histogram of the
chromosome number because it did not show the typical
peak in the diploid range. This was also observed by
DNA cytometry [5]. It can only be speculated whether
this distribution has any biological or clinical relevance
[23]. In this context we would like to mention that germ
cell tumors belong to those entities which frequently show
good response to chemotherapy and even spontaneous
tumor regression [10]. The histogram suggests that the
chromosomes numbers of germ cell tumor may be more
frequently in an unstable state between diploidy and
triploidy which may be associated with the above
mentioned phenomena.
Fig. 3 Analysis of percentage of cases with XX or XY numerical alterations in the different tumor entities (blue colour: percentage of cases in
men with XY numerical alterations; red colour: percentage of cases in women with XX numerical alterations)
Gender and ploidy in cancer survival 205By analyzing the 36.859 karyograms of the Mitelman
database we did not find a single case with normal
chromosome number (n=46) without at least one structural
or nummerical aberration suggesting that chromosomal
changes are an inherent feature of cancer formation.
Another observation of interest was the fact that
numerical aberrations of the sex chromosomes are more
prevalent in tumors from male compared to female patients.
The imbalance in relation to the two different gonosomes in
men may lead to an increased chromosomal instability.
This, in turn, may predispose to the accumulation of
additional chromosomal changes as the major cause for
tumor progression and cancer related death. Our observa-
tion and the above mentioned hypothesis represents a
possible biological cause for the phenomenon of worse
survival in men. However, it should be noted that the
difference in the number of changes of the sex chromo-
somes in the different tumor entities could not be
significantly associated with the difference in the gender-
specific survival rates. Apart from alterations of the sex
chromosomes, other factors probably play a role within
individual tumor types.
In conclusion, a significant survival advantage of women
could be shown for most cancer types. Triploidy is a
common phenomenon in many but not all tumor entities, its
extent is associated with poor prognosis in carcinomas.
Tumors of male patients more frequently harbour numerical
alterations of the sex chromosomes than tumors of females.
We suggest that the biological mechanisms underlying
gender specific differences in survival should be further
investigated. Also the role of triploidy in cancer biology
and progression merits more attention. Finally, our study
again highlights the fundamental importance of chromo-
somal changes in tumor biology.
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